C Nabhan

Summary

Affiliation: Lutheran General Hospital
Country: USA

Publications

  1. ncbi request reprint A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Chadi Nabhan
    Oncology Specialists, S C Lutheran General Hospital Cancer Care Center, Park Ridge, Illinois 60068, USA
    Leuk Lymphoma 45:2269-73. 2004
  2. ncbi request reprint It is follicular... . so, why CHOP?
    Chadi Nabhan
    J Clin Oncol 25:915-6; author reply 916-7. 2007
  3. pmc A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
    Chadi Nabhan
    Oncology Specialists, S C, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Avicenna J Med 1:12-7. 2011
  4. doi request reprint Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?
    Chadi Nabhan
    Oncology Specialists, SC and Division of Hematology Oncology, Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Leuk Lymphoma 53:1859-66. 2012
  5. doi request reprint The role of IMiDs alone or in combination in prostate cancer
    Chadi Nabhan
    Department of Medicine, Division of Hematology Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Clin Genitourin Cancer 10:141-6. 2012
  6. pmc Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
    C Nabhan
    Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Br J Cancer 107:592-7. 2012
  7. doi request reprint Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study
    Chadi Nabhan
    Department of Medicine, Division of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA
    Cancer 118:4842-50. 2012
  8. doi request reprint Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies
    Chadi Nabhan
    Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Leuk Lymphoma 53:770-8. 2012
  9. doi request reprint Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma
    Chadi Nabhan
    Oncology Specialists, S C, Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Clin Lymphoma Myeloma Leuk 12:26-31. 2012
  10. ncbi request reprint Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
    Chadi Nabhan
    Division of Hematology and Oncology, Lutheran General Hospital Cancer Center, Park Ridge, IL, USA
    Br J Haematol 136:379-92. 2007

Collaborators

Detail Information

Publications41

  1. ncbi request reprint A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
    Chadi Nabhan
    Oncology Specialists, S C Lutheran General Hospital Cancer Care Center, Park Ridge, Illinois 60068, USA
    Leuk Lymphoma 45:2269-73. 2004
    ..These studies are currently underway...
  2. ncbi request reprint It is follicular... . so, why CHOP?
    Chadi Nabhan
    J Clin Oncol 25:915-6; author reply 916-7. 2007
  3. pmc A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy
    Chadi Nabhan
    Oncology Specialists, S C, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Avicenna J Med 1:12-7. 2011
    ..To investigate the toxicity and efficacy of GM-CSF in castration-resistant prostate cancer (CRPC) patients who maximized their response to systemic chemotherapy...
  4. doi request reprint Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?
    Chadi Nabhan
    Oncology Specialists, SC and Division of Hematology Oncology, Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Leuk Lymphoma 53:1859-66. 2012
    ..AHSCT in first remission may have a role in selected patients with high-risk DLBCL, but a carefully designed prospective study is required to appropriately evaluate this concept...
  5. doi request reprint The role of IMiDs alone or in combination in prostate cancer
    Chadi Nabhan
    Department of Medicine, Division of Hematology Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Clin Genitourin Cancer 10:141-6. 2012
    ..This timely review coincides with the identification of newer therapies against CRPC affirming our steady movement toward better disease control...
  6. pmc Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
    C Nabhan
    Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Br J Cancer 107:592-7. 2012
    ..Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients...
  7. doi request reprint Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study
    Chadi Nabhan
    Department of Medicine, Division of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA
    Cancer 118:4842-50. 2012
    ..Racial differences in follicular lymphoma (FL) in the United States have not been investigated...
  8. doi request reprint Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies
    Chadi Nabhan
    Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Leuk Lymphoma 53:770-8. 2012
    ....
  9. doi request reprint Bortezomib (Velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-Hodgkin lymphoma
    Chadi Nabhan
    Oncology Specialists, S C, Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Clin Lymphoma Myeloma Leuk 12:26-31. 2012
    ..To evaluate the efficacy and toxicity of the combination of VRCD (velcade/rituximab/cyclophosphamide/dexamethasone) in chemotherapy-naïve low-grade non-Hodgkin lymphoma or patients with transplantation-ineligible mantle cells...
  10. ncbi request reprint Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
    Chadi Nabhan
    Division of Hematology and Oncology, Lutheran General Hospital Cancer Center, Park Ridge, IL, USA
    Br J Haematol 136:379-92. 2007
    ....
  11. doi request reprint Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Oncology Specialists, Lutheran General Hospital, Park Ridge, IL 60068, USA
    Urology 74:665-71. 2009
    ..To investigate the efficacy and toxicity of single-agent erlotinib in chemotherapy-naive castration-resistant prostate cancer...
  12. ncbi request reprint A simple wish...Unfulfilled
    Chadi Nabhan
    Lutheran General Hospital Cancer Institute, Park Ridge, IL 60068, USA
    J Clin Oncol 24:1217-8. 2006
  13. doi request reprint Controversies in the front-line management of chronic lymphocytic leukemia
    Chadi Nabhan
    Oncology Specialists, S C, Lutheran General Hospital, Department of Medicine, Division of Hematology and Medical Oncology, Park Ridge, IL 60068, USA
    Leuk Res 32:679-88. 2008
    ..The review is intended to discuss and simplify first-line therapy selection for patients with CLL in the era of new prognostic indicators and the better understanding of disease biology...
  14. doi request reprint Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?
    C Nabhan
    Department of Medicine, Division of Hematology and Oncology, Lutheran General Hospital, Park Ridge, IL 60068, USA
    Bone Marrow Transplant 45:1379-87. 2010
    ..We then analyze the data on HSCT in relapsed MCL and as a frontline approach propose applying the new prognostic index, MIPI (MCL International Prognostic Index), in the decision making...
  15. ncbi request reprint The emerging role of alemtuzumab in chronic lymphocytic leukemia
    Chadi Nabhan
    Oncology Specialists, SC, and Division of Hematology and Oncology, Lutheran General Hospital Cancer Care Center, 1700 Luther Lane, Park Ridge, IL 60068, USA
    Clin Lymphoma Myeloma 6:115-21. 2005
    ..This review summarizes the clinical experience with alemtuzumab that eventually led to its approval. Recent novel prognostic factors and trends in CLL therapy are also reviewed...
  16. doi request reprint Novel approaches and future directions in castration-resistant prostate cancer
    C Nabhan
    Department of Medicine, Division of Hematology and Oncology, Lutheran General Hospital, Park Ridge, IL 60068, USA
    Ann Oncol 22:1948-57. 2011
    ..This timely review coincides with the identification of newer therapies in this setting affirming our steady movement towards better disease control...
  17. doi request reprint Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies
    Chadi Nabhan
    Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA
    Leuk Lymphoma 52:374-86. 2011
    ..In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward...
  18. doi request reprint Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome
    Chadi Nabhan
    Division of Hematology Oncology, Advocate Lutheran General Hospital, 1700 Luther Lane, Park Ridge, IL, USA
    Br J Haematol 156:196-204. 2012
    ..Prospective studies for very elderly NHL that incorporate geriatric tools, especially ADLs, are warranted...
  19. doi request reprint Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients
    Chadi Nabhan
    Division of Hematology and Medical Oncology and Hematology and Oncology Fellowship Program, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA Illinois
    Cancer 117:1490-7. 2011
    ..The authors of this report investigated the safety and efficacy of clofarabine (CLO) in these patients...
  20. ncbi request reprint Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up
    Chadi Nabhan
    Department of Medicine, Division of Hematology Oncology, Advocate Lutheran General Hospital and Cancer Care Center, Park Ridge, IL 60078, USA
    Clin Colorectal Cancer 6:436-41. 2007
    ..We aimed to determine efficacy and tolerability of preoperative mitomycin, fluorouracil (5-FU), and leucovorin (LV) concurrent with hyperfractionated radiation therapy (RT) followed by surgery and adjuvant chemotherapy...
  21. pmc A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
    K Kruczek
    Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL, USA
    Br J Cancer 109:1711-6. 2013
    ..The mammalian target of rapamycin (mTOR) pathway is deregulated in castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of temsirolimus, an mTOR inhibitor, in chemotherapy-naïve CRPC...
  22. ncbi request reprint Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia
    Chadi Nabhan
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Semin Oncol 29:75-80. 2002
    ..This concept is being explored at our institution in the context of a phase I/II clinical trial. The outcome and feasibility of this combination opens the way for future combination therapies using novel biologic agents...
  23. ncbi request reprint Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung cancer: a phase II trial
    A Radhakrishnan
    Department of Medicine, Division of Hematology Oncology, Advocate Lutheran General Hospital, IL 60068, USA
    J Chemother 21:439-44. 2009
    ..9 months with 49% of patients alive at 1 year. Most common toxicities were nausea, vomiting, and dehydration. This combination has notable activity in advanced non-small cell lung cancer with a favorable toxicity profile...
  24. ncbi request reprint The role of bone marrow transplantation in acute promyelocytic leukemia
    C Nabhan
    Division of Hematology-Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Bone Marrow Transplant 28:219-26. 2001
    ..A randomized prospective clinical trial, or a retrospective analysis of the available data would be useful in answering this critical question...
  25. ncbi request reprint Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Clin Lymphoma 2:S19-23. 2002
    ..This agent is currently being investigated in many clinical trials as a front-line approach in previously untreated individuals, and it is likely that it will have many more indications in the near future...
  26. ncbi request reprint Current status of monoclonal antibody therapy for chronic lymphocytic leukemia
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Northwestern University, Medical School, Robert H Lurie, Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 17:253-62; discussion 264, 267, passim. 2003
    ..In this review, we discuss the clinical data on the activity of commercially available antibodies in CLL, both as monotherapy and in combination with other agents...
  27. ncbi request reprint Hodgkin's lymphoma involving the CNS
    Ewelina Morawa
    Department of Medicine, Lutheran General Hospital, Park Ridge, IL, USA
    J Clin Oncol 25:1437-8. 2007
  28. ncbi request reprint Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era
    Chadi Nabhan
    Oncology Specialists, S C, Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
    Leuk Res 28:429-42. 2004
    ..These drugs are increasingly used as initial therapy in CLL. Such strategies are associated with higher remission rates than have been previously achieved and in some cases, molecular remission, suggesting an important step towards cure...
  29. doi request reprint Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices
    A K Nooka
    Winship Cancer Institute, Division of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    Ann Oncol 24:441-8. 2013
    ..However, limited data exist regarding the role of FLIPI in the era of routine first-line rituximab (R) and R-chemotherapy regimens and in the setting of community oncology practices...
  30. ncbi request reprint Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease
    C Nabhan
    Oncology Specialists, S C, Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
    Ann Oncol 15:1231-6. 2004
    ..However, the majority of these studies were done in patients who had undergone high-dose therapy with stem cell transplantation or when GO was administered in combination with other cytotoxic chemotherapy...
  31. ncbi request reprint Management of acute promyelocytic leukemia
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Curr Oncol Rep 4:381-9. 2002
    ..Incorporation of such agents into the treatment of patients with high-risk disease may be an important future direction to pursue...
  32. ncbi request reprint Acute promyelocytic leukemia: evolving therapeutic strategies
    Martin S Tallman
    Division of Hematology and Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Medical School, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
    Blood 99:759-67. 2002
    ..As experience with ATRA and arsenic trioxide in patients with APL accumulates, a number of important questions arise that need to be addressed...
  33. ncbi request reprint Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older
    Chadi Nabhan
    S C Lutheran General Hospital Cancer Care Center, Park Ridge, IL, USA
    Leuk Res 29:53-7. 2005
    ..These early results suggest that the option of single agent monoclonal antibody therapy is viable in this patient population and that additional studies are warranted with this agent either alone or in combination as initial therapy...
  34. ncbi request reprint Caspase activation is required for gemcitabine activity in multiple myeloma cell lines
    Chadi Nabhan
    Division of Hematology and Oncology, Department of Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Mol Cancer Ther 1:1221-7. 2002
    ..There is a suggestion that mitochondrial integrity is being affected with gemcitabine in this system. Gemcitabine acts independently of interleukin 6, suggesting potential important therapeutic implications in MM patients...
  35. doi request reprint Frontline therapy for chronic lymphocytic leukemia: the dilemma continues
    Chadi Nabhan
    Clin Cancer Res 14:4353. 2008
  36. ncbi request reprint Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old
    Simrit Parmar
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
    Leuk Res 28:909-19. 2004
    ..All subjects had progressive disease. There was no direct treatment-related mortality. Based on this study, we do not recommend single agent ATO as a treatment option for AML...
  37. ncbi request reprint Should we transplant indolent lymphoma?
    Chadi Nabhan
    J Clin Oncol 23:6263-4; author reply 6264-6. 2005
  38. ncbi request reprint Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?
    Chadi Nabhan
    J Clin Oncol 24:2967-8; author reply 2968-9. 2006
  39. ncbi request reprint Chemotherapy for advanced prostate cancer
    Chadi Nabhan
    N Engl J Med 352:200-1; author reply 200-1. 2005
  40. ncbi request reprint Erlotinib in lung cancer
    Chadi Nabhan
    N Engl J Med 353:1739-41; author reply 1739-41. 2005
  41. ncbi request reprint Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer?
    Chadi Nabhan
    J Clin Oncol 26:2413-4; author reply 2414-5. 2008